Literature DB >> 16865310

Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept.

V Bagalas1, I Kioumis, P Argyropoulou, D Patakas.   

Abstract

Visceral leishmaniasis (VL) is a severe disease that can develop in immunocompromised patients. Antitumor necrosis factor-alpha (TNF-alpha) treatment of rheumatoid arthritis can result in clinical benefits, but with an increased risk of opportunistic infections. Leishmania infection in patients treated with TNF-alpha antagonists is extremely rare; for this reason, we report a patient with VL after etanercept treatment who had an unfavorable outcome.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16865310     DOI： 10.1007/s10067-006-0356-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  10 in total

1.  [Rare opportunistic disease in a patient treated with immunosuppressive therapy for rheumatoid arthritis].

Authors:  A Baixauli Rubio; E Rodríguez Górriz; C Campos Fernández; J Calvo Catalá; S García Vicente
Journal:  An Med Interna       Date:  2003-05

2.  Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab.

Authors:  S Fabre; C Gibert; C Lechiche; J Dereure; C Jorgensen; J Sany
Journal:  Clin Exp Rheumatol       Date:  2005 Nov-Dec       Impact factor: 4.473

Review 3.  Current management: Management of rheumatic diseases in the era of biological anti-rheumatic drugs.

Authors:  Yrjö T Konttinen; Seppo Seitsalo; Matti Lehto; Seppo Santavirta
Journal:  Acta Orthop       Date:  2005-10       Impact factor: 3.717

4.  Granulomatous infections due to tumor necrosis factor blockade: correction.

Authors:  Robert S Wallis; Michael Broder; John Wong; David Beenhouwer
Journal:  Clin Infect Dis       Date:  2004-10-15       Impact factor: 9.079

5.  Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism.

Authors:  S J Green; M S Meltzer; J B Hibbs; C A Nacy
Journal:  J Immunol       Date:  1990-01-01       Impact factor: 5.422

6.  Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies.

Authors:  E M Paleolog; R A Fava
Journal:  Springer Semin Immunopathol       Date:  1998

Review 7.  Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years.

Authors:  J D Berman
Journal:  Clin Infect Dis       Date:  1997-04       Impact factor: 9.079

8.  Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis.

Authors:  P P Tak; P C Taylor; F C Breedveld; T J Smeets; M R Daha; P M Kluin; A E Meinders; R N Maini
Journal:  Arthritis Rheum       Date:  1996-07

9.  Visceral leishmaniasis and HIV-1 co-infection in southern France.

Authors:  E Rosenthal; P Marty; I Poizot-Martin; J Reynes; F Pratlong; A Lafeuillade; D Jaubert; O Boulat; J Dereure; F Gambarelli
Journal:  Trans R Soc Trop Med Hyg       Date:  1995 Mar-Apr       Impact factor: 2.184

Review 10.  Cytokines in the treatment of leishmaniasis: from studies of immunopathology to patient therapy.

Authors:  J L Ho; R Badaro; D Hatzigeorgiou; S G Reed; W D Johnson
Journal:  Biotherapy       Date:  1994
  10 in total
  7 in total

1.  New challenges in the epidemiology and treatment of visceral leishmaniasis in periurban areas.

Authors:  Kathryn M Dupnik; Eliana L Nascimento; Joao F Rodrigues-Neto; Tatjana Keesen; Maria Zélia Fernandes; Iraci Duarte; Selma M B Jeronimo
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

2.  Visceral leishmaniasis in immunosuppressed Caucasian patient.

Authors:  Muhammad Toqeer; Nadeem Rahman; Mark W Whitehead; Diana Lockwood
Journal:  BMJ Case Rep       Date:  2012-05-08

3.  Long-term use of an antiinflammatory, curcumin, suppressed type 1 immunity and exacerbated visceral leishmaniasis in a chronic experimental model.

Authors:  Nagasuresh Adapala; Marion M Chan
Journal:  Lab Invest       Date:  2008-09-15       Impact factor: 5.662

4.  Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection?

Authors:  Maria G Tektonidou; Fotini N Skopouli
Journal:  Clin Rheumatol       Date:  2007-10-26       Impact factor: 2.980

5.  Tumor necrosis factor alpha neutralization has no direct effect on parasite burden, but causes impaired IFN-γ production by spleen cells from human visceral leishmaniasis patients.

Authors:  Neetu Singh; Rajiv Kumar; Christian Engwerda; David Sacks; Susanne Nylen; Shyam Sundar
Journal:  Cytokine       Date:  2016-06-30       Impact factor: 3.861

6.  Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression.

Authors:  Pau Bosch-Nicolau; Maria Ubals; Fernando Salvador; Adrián Sánchez-Montalvá; Gloria Aparicio; Alba Erra; Pablo Martinez de Salazar; Elena Sulleiro; Israel Molina
Journal:  PLoS Negl Trop Dis       Date:  2019-08-30

Review 7.  Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe.

Authors:  Ioannis D Xynos; Maria G Tektonidou; Dimitrios Pikazis; Nikolaos V Sipsas
Journal:  Emerg Infect Dis       Date:  2009-06       Impact factor: 6.883
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.